Valneva has bolstered its vaccines pipeline with a shot designed to protect against shigellosis – a major global health threat – licensed from LimmaTech Biologics.
Shares in genomics sequencing company Oxford Nanopore were rising sharply this morning after it announced an £80 million ($102 million) share placement that included a £50 million investmen
FibroGen has pulled the plug on its lead drug pamrevlumab after two failed trials in pancreatic cancer and immediately announced plans to shed three-quarters of its workforce.
Eisai and Biogen have reported data showing that the benefit of treatment with their Alzheimer's disease therapy Leqembi appears to build over time, with no increase in safety risks.
mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma.
It's possible that Alzheimer's disease could be added to the lengthening list of health conditions that can be improved by treatment with GLP-1 receptor agonists.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.